Clinical studyPravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: The Carotid Atherosclerosis Italian Ultrasound Study*
References (31)
- et al.
Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLACII)
Am J Cardiol
(1995) - et al.
Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St. Thomas' Atherosclerosis Regression Study (STARS)
Lancet
(1992) - et al.
Risk factors and raised atherosclerotic lesions in coronary and cerebral arteries
Arteriosclerosis
(1981) - et al.
Coronary angiography in 506 pa-tients with extracranial cerebrovascular disease
Arch Intern Med
(1985) - et al.
Individual susceptibility to extracranial carotid atherosclerosis
Arteriosclerosis
(1988) - et al.
Evaluation of the association between carotid artery atherosclerosis and coronary artery atherosclerosis
Stroke
(1990) - et al.
Strong correlation between carotid artery wall thickness and quantitative coronary artery angiography assessment of coronary atherosclerosis
Circulation
(1994) - et al.
Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging
Circulation
(1986) Noninvasive imaging protocols to detect and monitor carotid atherosclerosis progression
Am J Hypertens
(1994)The Atherosclerosis Risk in Communities (ARIC) study: design and objectives
Am J Epidemiol
(1989)
On behalf of the CHS Collaborative Research Group. Use of sonography to evaluate carotid atherosclerosis in the elderly. The Cardiovascular Health Study
Stroke
Risk factors for carotid atherosclerosis: the Kuopio Ischaemic Heart Disease Risk Factors Study
Ann Med
Cardiovascular determinants of carotid artery disease. The Rotterdam Study
Hypertension
Pravastatin intervention trial on carotid artery atherosclerosis in patients with mild hypercholesterolemia: the CAIUS study
Int J Cardiac Imag
Cited by (254)
The Japan Statin Treatment Against Recurrent Stroke (J-STARS) Echo Study: Rationale and Trial Protocol
2017, Journal of Stroke and Cerebrovascular DiseasesCitation Excerpt :Third, the study drug in this trial, pravastatin, is not a strong but rather a traditional statin. In addition, its daily dose of 10 mg is lower than that in the previous trials on statins and carotid IMT in Western countries (generally 40 mg daily).6-8 In Japanese, 10 mg daily of pravastatin seems to greatly reduce the LDL cholesterol level, although it is not certain if this dose is enough for stabilization of carotid plaque.
Time-related trends in variability of cIMT changes in statin trials
2016, Data in BriefChanging characteristics of statin-related cIMT trials from 1988 to 2006
2016, AtherosclerosisCitation Excerpt :While results from several clinical trials have indicated that lipid-lowering therapy (LLT) significantly reduced progression of cIMT [8–12], a meta-analysis of LLT trials showed no relationship of cIMT change to CVD risk [5]. In early clinical trials, statin effects on cIMT changes were positive and clinically relevant [8,13–19]; however, in some recent trials, cIMT change did not differentiate between lipid-lowering therapies where a difference would be expected based on existing clinical outcomes data [20,21], including the recently reported IMPROVE-IT trial [22,23]. It has been suggested that the predictive power of cIMT as a surrogate marker for assessment of CVD risk may be limited in some settings due to differences in trial design, cIMT methods, and patient characteristics [24–26].
A systematic review of statin-induced muscle problems in clinical trials
2014, American Heart JournalA systematic review of the time course of atherosclerotic plaque regression
2014, Atherosclerosis
- *
CAIUS was funded through independent research grants provided by Bristol-Myers Squibb S.p.A. Italy, and in part by a grant from the Italian National Research Council (C.N.R. Progetto Finalizzato, Invecchiamento, SP321).
- †
Prof. Giancario Descovich is deceased.